Skip to main content
OpenTrials
Completed

NCT Number: NCT05787041

The Effect of High Fat Diet on the Pharmacokinetics of AD16 Tablets in Healthy Chinese Adult Subjects

The study was a single-center, randomized, open-access, two-crossover, single-dose study design with 16 subjects to evaluate the pharmacokinetics of a high-fat diet on a single dose of oral AD16 tablets in healthy Chinese adults and the safety of a single dose of oral AD16 tablets in healthy Chinese adults.

Compared with fasting administration, a high-fat diet reduced the rate of AD16 tablet absorption in healthy adult subjects and had no effect on overall exposure to AD16.

The elimination and distribution characteristics of AD16 in vivo were similar under the conditions of feeding and fasting administration.

A single dose of AD16 tablets after fasting and high fat diet showed good safety.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

The Central South University Xiang Ya Hospital

Changsha, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Inclusion criteria

  • Healthy subjects were aged 18-45 years (including boundary values), male and female.
  • Weight ≥50kg (male) or ≥45kg (female), and body mass index (BMI) of 19-24kg/m2 (including the boundary values at both ends).
  • Have fully understood this study, voluntarily participated in it, and signed the Informed Consent.
  • Subjects are able to communicate well with researchers and complete the study according to protocol.
  • The subjects were deemed to be in good health based on physical examination, medical history, vital signs, electrocardiogram, chest X-ray, abdominal ultrasound, and laboratory tests.
  • Subject (including partner) is willing to have no pregnancy plan for the next 30 days (female subject) or 90 days (male subject) and is willing to use effective contraception.

Exclusion criteria

  • Positive for hepatitis B surface antigen, hepatitis C antibody, syphilis antibody or HIV antibody.
  • The patient has symptoms or related history of any serious disease, including but not limited to heart, liver, kidney, or other acute or chronic digestive tract or respiratory tract diseases, as well as diseases of the blood, endocrine, neurological, psychiatric and other systems, or any other disease or physiological condition that can interfere with the study results.
  • A history of postural hypotension with frequent episodes.
  • A history of frequent nausea or vomiting due to any cause.
  • Any clear history of drug or food allergies, especially allergies to ingredients similar to the drugs in this study.
  • Have special dietary requirements and cannot comply with the uniform diet provided by the clinical research center.
  • Previous drug abuse history or positive urine drug screening during screening period.
  • Smokers who smoked more than 5 cigarettes a day in the 3 months before the test.
  • Heavy drinkers or regular drinkers in the 6 months prior to the study screening, who drank more than 14 units of alcohol per week (1 unit of alcohol ≈360 mL beer or 45 mL 40% spirits or 150 mL wine) or had a positive alcohol breath test during the screening period.
  • Excessive consumption of tea, coffee (more than 6 cups) and/or caffeinated beverages (more than 1L) per day.
  • Take food or drink rich in xanthine, grapefruit or alcohol, caffeine (e.g., dragon fruit, mango, grapefruit, chocolate, coffee or tea) within 48 hours before administration.
  • Surgical procedures, transfusions of blood or blood components in the month prior to study screening.
  • Blood loss or donation of more than 400 mL in the 2 months prior to screening.
  • Participated in other clinical studies and took experimental drugs within 3 months prior to study screening.
  • Study participants who had received any medication in the 28 days prior to screening.
  • Pregnant or lactating women or women who have had unprotected sex within 14 days.
  • Those unable to complete the study for other reasons or deemed unsuitable for inclusion by the researcher.

Treatment and study plan

high-fat diet group(AD16 20mg)

Other

AD16 was administered with 240 mL water 30 minutes after the subjects ate a high-fat, high-calorie food.

fasted group(AD16 20mg)

Other

Subjects took AD16 on an empty stomach and fasted within 4 hours after taking the drug.

Primary outcomes

  1. Cmax of AD16

    Time frame: Up to Day 10

    Maximum (peak) plasma drug concentration

  2. AUC 0-t of AD16

    Time frame: Up to Day 10

    Area under the plasma concentration-time curve(AUC) from time zero to time t

  3. AUC 0-∞ of AD16

    Time frame: Up to Day 10

    Area under the plasma concentration-time curve(AUC) from time zero to infinity

  4. t1/2 of AD16

    Time frame: Up to Day 10

    Elimination half-life (to be used in a one-compartment or noncompartmental model)

  5. Tmax of AD16

    Time frame: Up to Day 10

    Time to reach the maximum (peak) plasma concentration following drug administration

  6. CL/F of AD16

    Time frame: Up to Day 10

    CL/F is defined as the ratio of total clearance(CL) to bioavailability(F).

  7. Vd/F of AD16

    Time frame: Up to Day 10

    Apparent volume of distribution after non-intravenous administration

  8. MRT of AD16

    Time frame: Up to Day 10

    Mean residence time(MRT)

  9. λz of AD16

    Time frame: Up to Day 10

    Terminal disposition rate constant/terminal rate constant

Secondary outcomes

  1. Adverse events

    Time frame: day-7 to day 10

    The number of adverse events

  2. Serious adverse events

    Time frame: day-7 to day 10

    The number of serious adverse events

  3. Number of participants with abnormal laboratory test results

    Time frame: day-7 to day-1 and day10

    Laboratory tests include blood routine, blood biochemistry, coagulation function and urine routine

  4. Number of participants with abnormal vital signs

    Time frame: day-7 to day3 and day7 to day10

    vital signs include Pulse, blood pressure, body temperature and respiratory rate were observed at different time points before and after medication.

  5. Number of participants with abnormal 12- Lead ECG readings

    Time frame: day-7 to day-1 and days3 、10

    abnormal 12- Lead ECG

  6. Number of participants with abnormal physical examination findings

    Time frame: day-7 to day-1 and day10

    The skin, mucosa, lymph nodes, head, neck, chest, abdomen, spine/limbs and nervous system were observed at different time points before and after medication.

  7. Concomitant medication

    Time frame: Up to Day 10

    Any concomitant medication

Sponsors and collaborators

Lead sponsor

South China Center For Innovative Pharmaceuticals

Other

Collaborators

  • Xiangya Hospital of Central South University

Registry information

Important dates

Study start
2019
Primary completion
2019
Study completion
2019
First posted
Mar 28, 2023
Registry last updated
Dec 1, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.